Top

Gepubliceerd in:

2011 | OriginalPaper | Hoofdstuk

29. Endocriene tumoren

Auteurs : Prof. dr. J. W. A. Smit, C. J. Lips, Th. P. Links, Dr. A. M. Pereira, Dr. E. P. M. van der Kleij-Corssmit, Dr. O. Dekkers, Prof. dr. J. Kievit, Dr. H. R. Haak, Prof. dr. J. A. Romijn, Prof. dr. P. T. A. M. Lips, Dr. W. de Herder, Dr. D. J. Kwekkeboom, C. H. J. van Eijck, Dr. R. A. Feelders

Gepubliceerd in: Oncologie

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

De endocriene oncologie betreft een uitgebreid vakgebied waarbij behalve de endocrinologie en oncologie andere disciplines, zoals de klinische farmacologie, heelkunde, pathologie, genetica en moleculaire biologie nauw zijn betrokken. Tumoren van endocriene cellen worden symptomatisch gekenmerkt door overproductie van hormonen of door massa-effect van de tumor, bijvoorbeeld een niet-functionerende-hypofysetumor. Soms zijn er weinig klachten, zoals bij metastasering van schildkliercarcinoom. Veel tumoren produceren ectopisch hormonen, waardoor specifieke klinische beelden kunnen ontstaan.

vorige hoofdstuk Tumoren van het zenuwstelsel

volgende hoofdstuk Tumoren van de oogleden, ogen en orbita

Pearse AGE. The diffuse neuroendocrine system and the ‘common peptides’. In: McIntyre I, Szelke M (eds). Proceedings of endocrinology 1977. Royal College of Physicians. London: Elsevier North Holland Biomedical Press, 1977:309–324.

Pearson PL, Luijt RB van der. The genetic analysis of cancer. J Int Med 1998;243:413-7.CrossRef

Ried T. Cytogenetics - in color and digitized. Perspective. N Engl J Med 2004; 350:1597–1600.CrossRef

Vijver MJ van de, He YD, Veer LJ van ‘t, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.CrossRefPubMed

Vogelstein B, Kinzler KW (eds). The genetic base of human cancer. New York: McGraw-Hill Inc., 1998:475–88.

Yeatman TJ. The future of cancer management: translating the genome, transcriptome, and proteome. Ann Surg Oncol 2003;10:7–14.CrossRefPubMed

Alexander EK, Hurwitz S, Heering JP, Benson CB et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003;138:315–8.CrossRefPubMed

CBO-richtlijn Gedifferentieerd schildkliercarcinoom (www.oncoline.nl).

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mclver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–42.CrossRefPubMed

Kloos RT, Eng Ch, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA. Medullary thyroid cancer: Management guidelines of the American Thyroid Association The American Thyroid Association Guidelines Task Force. Thyroid 2009;19:565–612.CrossRefPubMed

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.CrossRefPubMed

Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31–42.CrossRefPubMed

Shibru D, Chung KW, Kebebew E. Recent developments in the clinical application of thyroid cancer biomarkers. Review Curr Opin Oncol. 2008 Jan;20(1):13-8.CrossRefPubMed

Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss, 2002:52–6.

Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335–9.CrossRefPubMedPubMedCentral

Björklund P, Lindberg D, Akerström G, Westin G. Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer 2008;7:53.CrossRefPubMedPubMedCentral

Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab 2005;90:6316–22.CrossRefPubMed

Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyreoidism: Proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:373–81.CrossRefPubMed

Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373–9.CrossRefPubMed

Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266–81.CrossRefPubMed

Stewart PM. Mineralocorticoid hypertension. Lancet 1999;353:1341–7.CrossRefPubMed

Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma clinical update. J Clin Endocrinol Metab 2006;91:2027–37.CrossRefPubMed

Ditzhuijsen CIM van, Weijer R van de, Haak HR. Adrenocortical carcinoma. Neth J Med 2007;65:55–9.PubMed

Benn DE, Gimenez-Roqueplo A, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PLM, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin P, Robinson BG. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91(3):827–36.CrossRefPubMed

Havekes B, Lai EW, Corssmit EPM, Romijn JA, Timmers HJLM, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET scanning. Q J Nucl Med Mol Imaging 2008;52(4):419-29.PubMed

Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004;89:479–91.CrossRefPubMed

Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. Von Hippel-Lindau disease. Lancet 2003;361:2059–67.CrossRefPubMed

Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peçzkowska M, Szmigielski C, Eng C. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–66.CrossRefPubMed

Pacak K. Preoperative management of the pheochromocytoma patient. Review. J Clin Endocrinol Metab 2007;92:4069–79.CrossRefPubMed

Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Ann Intern Med 2003;138(5):424-9.CrossRefPubMed

Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007;14(3):587–99.CrossRefPubMed

Kievit J, Haak HR. Diagnosis and treatment of adrenal incidentaloma. A cost-effectiveness analysis. Endocrinol Metab Clin North Am 2000;29(1):69-ix.CrossRefPubMed

Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25(2):309-40.CrossRefPubMed

Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85(2):637–44.

Song JH, Chaudhry FS, Mayo-Smith WW. The incidental indeterminate adrenal mass on CT (> 10 H) in patients without cancer: is further imaging necessary? Follow-up of 321 consecutive indeterminate adrenal masses. AJR Am J Roentgenol 2007;189(5):1119-23.CrossRefPubMed

Newell-Price J, Bertagna X, Grossman AB, Nieman LK et al. Cushing’s syndrome. Lancet 2006;13;367(9522):1605.

Pereira AM, Aken MO van, Dulken H van, Schutte PJ, Biermasz NR, Smit JWA, Roelfsema F, Romijn JA. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing’s disease. J Clin Endocrinol Metab 2003;(88):5858–64.CrossRefPubMed

Biermasz NR, Dekker FW, Pereira AM, Thiel SW van, Schutte PJ, Dulken H van, Romijn JA, Roelfsema F. Determinants of survival in treated acromegaly in a single center: predictive value of serial IGF-1 measurements. J Clin Endocrinol Metab 2004;89(6):2789–96.CrossRefPubMed

Biermasz NR, Dulken H van, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85:2476–82.CrossRefPubMed

Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, Aken MO van, Voormolen JH, Romijn JA. Mortality in patients treated for Cushing’s disease is increased compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007;92(3):976-8I.CrossRefPubMed

Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006;91(5):1796-801.CrossRefPubMed

Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM. Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008;93(9):3348–56.CrossRefPubMed

Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, Thiel SW van, Corssmit EP, Smit JW, Roelfsema F, Romijn JA. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf) 2005;62(2):197–204.CrossRef

Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, Jensen R, Kos-Kudla B, Oberg K, O’Connor JM, Pavel ME, Vullierme MP. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008;87:40–6.CrossRefPubMed

Herder WW de, Krenning EP, Eijck CH van, Lamberts SW. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 2004;11:19–34.CrossRefPubMed

Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511.CrossRefPubMed

Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858–68.CrossRefPubMed

Kwekkeboom DJ, Herder WW de, Kam BL, Eijck CH van, Essen M van, Kooij PP, Feelders RA, Aken MO van, Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.CrossRefPubMed

Modlin IM, Oberg K, Chung DC, Jensen RT, Herder WW de, Thakker RV, Caplin M, Delle FG, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72.CrossRefPubMed

Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY, Garcia MI, Caplin ME. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008;87:31–9.CrossRefPubMed

Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, Mc-Nicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451^:757-62.CrossRefPubMed

Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ. CONSENSUS: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658–71.CrossRefPubMed

Los M, Links TP, Lenders JW, Voest EE. De ziekte van Von Hippel-Lindau. Ned Tijdschr Geneeskd 2000;144:497–501.PubMed

Hofstra RM, Luijt RB van der, Lips CJ. Van gen naar ziekte; van het RETgen naar multipele endocriene neoplasie type 2A en 2B, sporadisch en familiair medullair schildkliercarcinoom, ziekte van Hirschsprung en papillair schildkliercarcinoom. Ned Tijdschr Geneeskd 2001;145:2217–21.PubMed

Titel: Endocriene tumoren
Auteurs: Prof. dr. J. W. A. Smit
C. J. Lips
Th. P. Links
Dr. A. M. Pereira
Dr. E. P. M. van der Kleij-Corssmit
Dr. O. Dekkers
Prof. dr. J. Kievit
Dr. H. R. Haak
Prof. dr. J. A. Romijn
Prof. dr. P. T. A. M. Lips
Dr. W. de Herder
Dr. D. J. Kwekkeboom
C. H. J. van Eijck
Dr. R. A. Feelders
Uitgeverij: Bohn Stafleu van Loghum
Boek: Oncologie
Print ISBN: 978-90-313-6231-8

Elektronisch ISBN: 978-90-313-8476-1

Copyright: 2011
DOI: https://doi.org/10.1007/978-90-313-8476-1_29

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen